Literature DB >> 16410672

Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells.

Yuko Nishina1, Koji Takano, Junko Yasufuku-Takano, Akira Teramoto, Toshiro Fujita.   

Abstract

The mechanism of dopamine D(2) agonist-induced inhibition of GH secretion from GH-secreting adenoma cells was investigated by measurement of intracellular calcium concentration ([Ca(2+)] (i)) and static incubation experiment. Bromocriptine decreased [Ca(2+)](i) in a concentration-dependent manner through D(2) receptor. The inhibition was abolished by pertussis toxin pretreatment. Bromocriptine did not decrease [Ca (2+)](i) after nitrendipine had decreased it. 8Br-cAMP increased [Ca(2+)](i) but application of bromocriptine decreased it, suggesting that bromocriptine-induced inhibition of [Ca(2+)](i) is not dependent on bromocriptine-induced inhibition of adenylyl cyclase. Static incubation experiment revealed that bromocriptine inhibited GH secretion in a concentration-dependent manner. The inhibition was through D(2) receptor and was abolished by pertussis toxin pretreatment. 8Br-cAMP increased GH secretion. Bromocriptine decreased GH secretion even after 8Br-cAMP pretreatment. However, the GH release from cells incubated with bromocriptine alone was significantly less than that from cells incubated with bromocriptine after 8Br-cAMP pretreatment, suggesting a modulatory action of cAMP system in bromocriptine response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16410672     DOI: 10.1507/endocrj.52.775

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  2 in total

1.  Effect of ghrelin and metoclopramide on prolactin secretion in normal women.

Authors:  C I Messini; K Dafopoulos; N Chalvatzas; P Georgoulias; G Anifandis; I E Messinis
Journal:  J Endocrinol Invest       Date:  2010-06-04       Impact factor: 4.256

2.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.